Lexington Biosciences Inc.

LNB on CSEToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
0.49CAN 0.01/1.04%378,5750.27 / 0.4914.91 M
LXGTF on OTCQBToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
0.39US 0.00/0.60%364,0780.25 / 0.4111.91 M

Contact Information

Lexington Biosciences Inc.

Headquarters:
5470 Kietzke Lane, Suite 300
Reno, Nevada
USA, 89511
Tel: 1 (800) 320-2640
Email: Send a message
Website: Visit website
For more information...
Lead: Laura Welsh

Lexington Biosciences is a medical device company that is developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium — the vital innermost lining of a person’s cardiovascular system. Traditionally, this has only been measured using ultrasound and other complex, difficult to use technologies. The HeartSentry technology core research was created at the University of California Berkeley over a fifteen-year period involving many studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. The company is in the final stages of releasing the developed product for clinical studies. The aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit www.lexingtonbiosciences.com/company/about-us/ and watch our video.

Eric Willis - President

Jonathan S. Maltz, PhD. - Chief Scientific Advisor

Donald A. McInnes - Advisor

Doug Janzen - Chairman

Rocco Rossi - Director

Bryan Disher - Director (Audit Committee)

Stock Information

Company Overview

Lexington Biosciences is a medical device company that is developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium — the vital innermost lining of a person’s cardiovascular system. Traditionally, this has only been measured using ultrasound and other complex, difficult to use technologies. The HeartSentry technology core research was created at the University of California Berkeley over a fifteen-year period involving many studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. The company is in the final stages of releasing the developed product for clinical studies. The aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit www.lexingtonbiosciences.com/company/about-us/ and watch our video.

Management

Eric Willis - President

Jonathan S. Maltz, PhD. - Chief Scientific Advisor

Donald A. McInnes - Advisor

Board of Directors

Doug Janzen - Chairman

Rocco Rossi - Director

Bryan Disher - Director (Audit Committee)

Contact Information

Headquarters:
5470 Kietzke Lane, Suite 300
Reno, Nevada
89511, USA
Telephone: 1 (800) 320-2640
Email: Send a message
Website: Visit website